Abstract
To evaluate the pharmacodynamic dose-response relationship of insulin degludec/insulin aspart (IDegAsp), a novel, soluble co-formulation of the ultra-long-acting basal insulin, insulin degludec (IDeg), with the rapid-acting prandial insulin (IAsp), across different doses in patients with type 1 diabetes (T1DM). This was a randomized, single-centre, double-blind, four-period, incomplete block, crossover trial. A cohort of 33 people with T1DM received single doses (0.4, 0.6 or 0.8 U/kg) of IDegAsp or the comparator, biphasic insulin aspart 30, in a randomized sequence of four treatment periods, each separated by a washout of 13-21 days. Pharmacodynamic response was assessed using a 26-h euglycaemic glucose clamp, with blood glucose stabilized at a target of 5.5 mmol/l (100 mg/dl). A rapid onset of action and a distinct peak attributable to IAsp was observed in the glucose infusion rate (GIR) profile, followed by a separate, flat and stable basal glucose-lowering effect attributable to the IDeg component. The mean area under the GIR curve over 24 h (AUC(GIR,0-24 h)), and the mean maximum GIR (GIR(max)) increased with increasing dose level of IDegAsp. A dose-response relationship for IDegAsp was demonstrated for AUC(GIR,0-24 h) and...Continue Reading
References
Oct 7, 1997·Diabetes Care·C WeyerL Heinemann
Aug 19, 2007·Clinical Therapeutics·Koichi HiraoTomio Sasaki
Jul 23, 2008·Diabetes, Obesity & Metabolism·A LieblUNKNOWN PREFER Study Group
Dec 4, 2008·Diabetes Technology & Therapeutics·T HeiseL Nosek
Oct 13, 2009·Diabetes, Obesity & Metabolism·A J Garber
Oct 24, 2009·The New England Journal of Medicine·Rury R HolmanUNKNOWN 4-T Study Group
Jan 29, 2010·Diabetes Care·UNKNOWN American Diabetes Association
Mar 18, 2011·Diabetes, Obesity & Metabolism·M EvansA B King
Mar 1, 2012·Diabetes Care·Eda CengizStuart A Weinzimer
Apr 10, 2012·Pharmaceutical Research·Ib JonassenUlla Ribel
Apr 21, 2012·Diabetes Care·Silvio E InzucchiUNKNOWN European Association for the Study of Diabetes (EASD)
May 19, 2012·Diabetes, Obesity & Metabolism·T HeiseH Haahr
Sep 22, 2012·Diabetes Care·Helena W Rodbard, Paul S Jellinger
Sep 22, 2012·Diabetes Care·Andrea GiaccariSimona Frontoni
Oct 15, 2013·Diabetes, Obesity & Metabolism·M C RiddleL Gao
Feb 15, 2014·World Journal of Clinical Cases·Carlton Robert FenzlJason Goldsmith
May 9, 2014·Diabetes Care·Gregory R FulcherLeo K Niskanen
Jun 4, 2014·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Tim HeiseHanne Haahr
Sep 3, 2014·Clinical Pharmacokinetics·Hanne Haahr, Tim Heise
Jan 8, 2015·Pharmaceutical Research·Svend HavelundIb Jonassen
Citations
Nov 26, 2015·Diabetes, Obesity & Metabolism·H W RodbardJ G Cooper
Nov 4, 2016·Pediatric Diabetes·Torben BiesterHanne Haahr
Oct 6, 2015·Diabetic Medicine : a Journal of the British Diabetic Association·E FranekJ S Christiansen
Jun 20, 2015·Drugs & Aging·Martina BrunnerHanne Haahr
May 18, 2016·Journal of Diabetes Investigation·Hanne HaahrIppei Ikushima
Jul 8, 2016·International Journal of Clinical Practice·A KumarJ S Christiansen
Oct 4, 2016·Clinical Pharmacokinetics·Hanne HaahrTim Heise
Aug 26, 2016·Journal of Diabetes Investigation·Yukiko OnishiYasuhiko Iwamoto
Feb 14, 2017·Diabetes Technology & Therapeutics·Thomas DanneJan Bolinder
Nov 2, 2019·Current Drug Targets·Ping WuHao Fang
May 13, 2020·Endocrine Reviews·Irl B HirschEugene E Wright
Feb 17, 2018·Diabetes, Obesity & Metabolism·Martin HaluzíkHelena W Rodbard
Aug 22, 2018·Diabetology & Metabolic Syndrome·Kanta FujimotoNaoki Matsuoka
Nov 24, 2016·Clinical Pharmacokinetics·Tim HeiseHanne Haahr
Apr 16, 2020·Journal of Clinical Medicine·Sarah J GlastrasGreg R Fulcher
Jan 17, 2021·BMJ Open Diabetes Research & Care·Ilze Dirnena-FusiniSverre Christian Christiansen
Jan 26, 2021·Archives of Medical Science : AMS·Serhat ÖzçelikHulya Gozu
Sep 18, 2021·Diabetes, Obesity & Metabolism·Ravi Retnakaran, Bernard Zinman